MedTrace Logo

A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma

NCT01025206 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2013-03-15

No results posted yet for this study

Summary

This is a first in human study which will assess the safety and tolerability of a monoclonal antibody against ICAM-1 in patients with Multiple Myeloma. The tumour response rate will also be measured.

Conditions

Interventions

BIOLOGICAL

BI-505

Anti-ICAM-1 monoclonal antibody given as a i.v infusion every second week for four weeks,

Sponsors & Collaborators

  • BioInvent International AB

    lead INDUSTRY

Principal Investigators

  • Guido Tricot, MD, PhD, Prof. · University of Utah

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • United States
  • Belgium
  • Denmark
  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01025206 on ClinicalTrials.gov